Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Score predicts locoregional recurrence of breast cancer

Key clinical point: The 21-gene assay recurrence score is an independent predictor of locoregional recurrence in postmenopausal patients with node-positive breast cancer.

Major finding: Having intermediate or high recurrence scores was a significant predictor of locoregional recurrence in a multivariable analysis, with a hazard ratio of 2.36 (P = .04).

Study details: A retrospective analysis of 316 patients from a phase 3 study

Disclosures: This research was funded by the National Cancer Institute of Canada, Canadian Cancer Society, and Genomic Health, which markets the 21-gene assay OncotypeDX. Dr. Woodward disclosed receiving personal fees from Genomic Health outside this research as well as an advisory fee from Merck.

Citation:

Woodward WA et al. JAMA Oncol. 2020 Jan 9. doi: 10.1001/jamaoncol.2019.5559.